




RealRate

MEDICINAL PRODUCTS 2019

Celldex Therapeutics Inc.
Rank 37 of 50





RealRate

MEDICINAL PRODUCTS 2019

Celldex Therapeutics Inc. Rank 37 of 50



The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable General and Administrative Expense, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is -49%, being 43% points below the market average of -5.9%.

Input Variable	Value in 1000 USD
Assets, Current	99,079
Assets, Non-Current	1,929
General and Administrative Expense	19,269
Goodwill	48,690
Liabilities, Current	12,602
Liabilities, Non-Current	19,147
Other Assets	0
Other Compr. Net Income	19
Other Expenses	79,491
Other Liabilities	0
Other Net Income	0
Other Revenues	14,025
Property, Plant and Equipment, Net	6,111
Research and Development	66,449

Output Variable	Value in 1000 USD
Liabilities	31,749
Assets	155,809
Expenses	165,209
Revenues	14,025
Stockholders Equity	124,060
Net Income	-151,184
Comprehensive Net Income	-151,174
Economic Capital Ratio	-49%